药学学报, 2016, 51(10): 1616-1621
引用本文:
王慧敏, 魏国光, 高明月, 顾香芹, 毛世瑞. 酒石酸卡巴拉汀鼻腔吸收及脑靶向性评价[J]. 药学学报, 2016, 51(10): 1616-1621.
WANG Hui-min, WEI Guo-guang, GAO Ming-yue, GU Xiang-qin, MAO Shi-rui. Intranasal absorption of rivastigmine hydrogen tartrate and brain targeting evaluation[J]. Acta Pharmaceutica Sinica, 2016, 51(10): 1616-1621.

酒石酸卡巴拉汀鼻腔吸收及脑靶向性评价
王慧敏, 魏国光, 高明月, 顾香芹, 毛世瑞
沈阳药科大学药学院, 辽宁 沈阳 110016
摘要:
本文研究了影响酒石酸卡巴拉汀鼻腔吸收的因素,考察了其体内药代动力学行为并评价了其脑靶向性。采用大鼠在体鼻腔循环法研究酒石酸卡巴拉汀浓度和药液pH值对药物鼻腔吸收的影响;大鼠静脉注射及鼻腔给药后,采用高效液相色谱(high performance liquid chromatography,HPLC)法测定血浆及脑组织中药物浓度,并计算药动学参数、脑靶向指数(drug targeting index,DTI)和药物鼻脑直接转运百分比(nose-to-brain directtransport percentage,DTP)。研究表明,酒石酸卡巴拉汀在鼻腔内的吸收机制为被动扩散,pH 6.0时药物吸收速率常数最大。该药物鼻腔给药的绝对生物利用度为73.58%。与静脉注射相比,鼻腔给药后药物入脑更加迅速,在脑组织的分布显著增加,DTI为静脉注射的195.27%。鼻腔给药后约48.79%药物可从鼻腔通道直接转运至脑部而未经全身血液循环,显著提高了药物的入脑速度和程度。同时,与静脉注射相比,酒石酸卡巴拉汀在脑部的清除半衰期延长了1.4倍。综上,酒石酸卡巴拉汀鼻腔给药不仅可有效促进药物的吸收,而且能显著加快药物的入脑速度和增强药物的脑组织分布,更有利于中枢神经系统疾病的治疗。
关键词:    酒石酸卡巴拉汀      鼻腔在体循环      鼻腔给药      脑靶向     
Intranasal absorption of rivastigmine hydrogen tartrate and brain targeting evaluation
WANG Hui-min, WEI Guo-guang, GAO Ming-yue, GU Xiang-qin, MAO Shi-rui
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract:
To investigate factors influencing the intranasal absorption of rivastigmine hydrogen tartrate (RHT), we studied the pharmacokinetics of RHT after intranasal administration and evaluated its brain targeting behavior. In situ rat nasal perfusion model was used in the study and pH impact was examined on the intranasal absorption of RHT. High performance liquid chromatography (HPLC) method was established to measure RHT concentration in the plasma and brain tissue after intranasal and intravenous administration. The pharmacokinetic parameters, drug targeting index (DTI), and nose-to-brain direct transport percentage (DTP) were calculated. It was demonstrated that the intranasal absorption mechanism of RHT was passive diffusion. The absorption rate was highest at pH 6.0. The absolute bioavailability of intranasally administrated RHT was 73.58%. Compared with that of intravenous administration, RHT absorption into the brain was faster and more efficient after intranasal delivery, and the DTI value was 195.27% of intravenous injection. Moreover, 48.79% of the drug can be absorbed directly from the nose into the brain without systematic circulation. Meanwhile, drug elimination half-time in the brain was prolonged by 1.4 fold compared to that of intravenous injection. In conclusion, intranasal administration of RHT not only improves drug absorption into the system, but also enhances drug absorption rate and content in the brain remarkably, which is an advantage in the treatment of central nervous system-related diseases.
Key words:    rivastigmine hydrogen tartrate    in situ nasal perfusion    intranasal delivery    brain targeting   
收稿日期: 2016-04-20
DOI: 10.16438/j.0513-4870.2016-0373
基金项目: 国家基础科学人才培养基金资助项目(J1103606).
通讯作者: 毛世瑞
Email: maoshirui@vip.sina.com
相关功能
PDF(1149KB) Free
打印本文
0
作者相关文章
王慧敏  在本刊中的所有文章
魏国光  在本刊中的所有文章
高明月  在本刊中的所有文章
顾香芹  在本刊中的所有文章
毛世瑞  在本刊中的所有文章

参考文献:
[1] Zhou NN, Zhu R, Zhao XM, et al. Effect and mechanism of gastrodin inhibiting β-amyloid plaques in brain of mice[J]. Acta Pharm Sin (药学学报), 2016, 51:588-594.
[2] Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles fo r drug delivery through the blood-brain barrier for Alzheimer's disease[J]. J Control Release, 2005, 108:193-214.
[3] Christiane R, Richard M. Alzheimer disease:epidemiology, diagnostic criteria, risk factors and biomarkers[J]. Biochem Pharmacol, 2014, 88:640-651.
[4] Yuan DF, Zong TL, Gao HL, et al. Cell penetrating peptide TAT and brain tumor targeting peptide T7 dual modified liposome preparation and in vitro targeting evaluation[J]. Acta Pharm Sin (药学学报), 2015, 50:104-110.
[5] Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route[J]. J Control Release, 2014, 189:133-140.
[6] Williams BR, Nazarians A, Gill MA. A review of rivastigmine:a reversible cholinesterase inhibitor[J]. Clin Ther, 2003, 25:1634-1653.
[7] Mohammad H, Stanford SJ, Thomas S, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type[J]. Clin Pharmacokinet, 2002, 41:225-234.
[8] Tayebati SK, Nwankwo IE, Amenta F. Intranasal drug delivery to the central nerous system:present status and future outlook[J]. Curr Pharm Design, 2013, 19:510-526.
[9] Yang ZZ, Zhang YQ, Wang ZZ, et al. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration[J]. Int J Pharm, 2013, 452:344-354.
[10] Mei D, Mao SR, Sun W, et al. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats[J]. Eur J Pharm Biopharm, 2008, 70:874-881.
[11] Na LD, Mao SR, Wang J, et al. Comparison of different absorption enhancers on the intranasal absorption of isosorbide dinitrate in rats[J]. Int J Pharm, 2010, 397:59-66.
[12] Na LD, Wang J, Wang LL, et al. A novel permeation enhancer:N-succinyl chitosan on the intranasal absorption of isosorbide dinitrate in rats[J]. Eur J Pharm Sci, 2013, 48:301-306.
[13] Song X, Du SY, Lu Y, et al. Study on rat nasal absorption in situ of borneol based on single pass perfusion method[J]. Chin J Chin Mater Med (中国中药杂志), 2011, 36:2489-2492.
[14] Yang ZZ, Zhang YQ, Wu K, et al. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats[J]. Curr Alzheimer Res, 2012, 9:315-325.
[15] Arumugam K, Chamallamudi MR, Mallayasamy SR, et al. High performance liquid chromatographic fluorescence detection method for the quantification of rivastigmine in rat plasma and brain:application to preclinical pharmacokinetic studies in rats[J]. J Young Pharm, 2011, 3:315-321.
[16] Li Y, Li JF, Zhang X, et al. Non-ionic surfactants as novel intranasal absorption enhancers:in vitro and in vivo characterization[J]. Drug Deliv, 2015, 21:1-8.
[17] Zhang QZ, Jiang XG, Jiang WM, et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain[J]. Int J Pharm, 2004, 275:85-96.
[18] Olivier JC, Djilani M, Fahmy S, et al. In situ nasal absorption of midazolam in rats[J]. Int J Pharm, 2001, 213:187-192.
[19] Lu Y, Chen XL, Du SY, et al. The in situ and in vivo study on enhancing effect of borneol in nasal absorption of geniposide in rats[J]. Arch Pharm Res, 2010, 33:691-696.
[20] Lu Y, Hao B, Wen R, et al. Comparative study on rat in situ nasal absorption of geniposide of Xingnaojing nasal drop and Xingnaojing microemulsion[J]. Chin J Chin Mater Med (中国中药杂志), 2013, 38:1510-1512.